Traditional MedicareCoverageMedium impact
Aprepitant for Chemotherapy-Induced Emesis
Medicare/CMS - NCD·Oncology, Hematology·National Coverage Determination
Effective date
Apr 30, 2026
We identified it
Jun 17, 2026
Summary
This is a National Coverage Determination for Aprepitant, a medication used to prevent chemotherapy-induced nausea and vomiting. The policy establishes Medicare coverage criteria for this anti-emetic drug when used in conjunction with cancer treatment.
Action Required
By April 30, 2026: Billing team must review the complete NCD 110.18 policy text to understand Medicare coverage criteria for Aprepitant. Update prior authorization processes and documentation requirements for chemotherapy-induced emesis treatments. Ensure providers understand any medical necessity requirements for this anti-emetic medication.